Clinical trial SERENA-4
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2020-002276-12 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04711252 |
| Inclusion criteria | ER+, HER2 -, Measurable disease by RECIST v1.1 or bone-only disease, PS 0-1 |
| Last update |